Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Liraglutide and Semaglutide Market

Liraglutide and Semaglutide Market Size

Report ID: GMI5886
Published Date: May 2023
Report Format: PDF

Download Free Sample

Liraglutide and Semaglutide Market Size

Liraglutide and Semaglutide Market size valued at USD 14.2 billion in 2022 and is estimated to grow at a 11.3% CAGR between 2023 to 2032. Increasing prevalence diabetes coupled with increasing awareness regarding obesity is expected to boost the market growth.

To get key market trends

Download Free Sample

Liraglutide and semaglutide are pharmaceutical medications categorized as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). They are used primarily in the treatment of type 2 diabetes and obesity. Liraglutide and semaglutide act by mimicking the effects of the GLP-1 hormone in the body, helping to regulate blood sugar levels, promote weight loss, and reduce the risk of cardiovascular complications.

Liraglutide and Semaglutide Market Report Attributes
Report Attribute	Details
Base Year:	2022
Liraglutide and Semaglutide Market Size in 2022:	USD 14.2 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	11.3%
2032 Value Projection:	USD 41.2 Billion
Historical Data for:	2018 to 2022
No. of Pages:	150
Tables, Charts & Figures:	364
Segments covered:	Type, Route of Administration, Application, Distribution Channel and Region
Growth Drivers:	Rising prevalence of type 2 diabetes Increasing obese population in developed nations Increasing R&D investments to enhance clinical efficacy
Pitfalls & Challenges:	Adverse side effects associated with use of liraglutide and semaglutide

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of liraglutide and semaglutide accounted for over USD 14 billion in 2022 and is estimated to cross USD 41 billion by 2032, on account of increasing prevalence diabetes and rising awareness regarding obesity, as the products are used primarily in the treatment of type 2 diabetes and obesity.

The type 2 diabetes mellitus segment is expected to grow at a 11.4% CAGR during 2023 and 2032, owing to product ability to effectively control blood sugar levels by stimulating insulin release and reducing the production of glucagon.

North America accounted for over 71% of the market share in 2022 and is anticipated to grow at considerable rate through 2032, backed by increasing occurrence of diabetes and rising awareness regarding the importance of disease management.

Novo Nordisk A/S, HEC Pharma Co., Shenzhen JYMed Technology Co. Ltd., Bachem Holding AG among others.